
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
Keywords: ADC; antibody-drug conjugate; NHL; non-Hodgkin lymphoma; DLBCL; diffuse large B-cell lymphoma; ADCC; antibody-dependent cell-mediated cytotoxicity; CDC; complement-dependent cytotoxicity; MMAE; monomethyl auristatin E; SMCC; N-succinimidyl-4-(N-maleimidoe